Trevi Therapeutics to Present at H.C. Wainwright Global Investment Conference
September 09, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics Announces Second Quarter 2020 Financial Results and Business Update
August 13, 2020 16:05 ET
|
Trevi Therapeutics
Announced Positive Outcome of Sample Size Re-Estimation Analysis for PRISM Trial Strong Enrollment in PRISM Trial After Lifting of COVID-19 Restrictions Announces $14 Million Term Loan - Cash...
Trevi Therapeutics to Report Q2 2020 Financial Results on August 13
August 06, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics to Present at BTIG Virtual Biotechnology Conference
August 05, 2020 07:30 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics Announces Positive Outcome of the Sample Size Re-Estimation Analysis in PRISM Trial for Severe Pruritus in Patients With Prurigo Nodularis
July 13, 2020 07:30 ET
|
Trevi Therapeutics
Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design Enrollment Expected to be Complete by Third Quarter 2021 ...
Trevi Therapeutics Announces Election of Dominick C. Colangelo to Board of Directors
June 30, 2020 16:45 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER...
Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Virtual Conference
June 17, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics to Hold Virtual 2020 Annual Meeting of Stockholders
May 29, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., May 29, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics Announces First Quarter 2020 Financial Results and Corporate Update
May 07, 2020 16:05 ET
|
Trevi Therapeutics
Sample Size Re-Estimation Analysis for PRISM Trial Expected in Mid-2020 New Patient Screening Re-Starting at PRISM Sites in the US and Europe Cash Position of $52.6 Million Expected to Fund...
TREVI THERAPEUTICS TO PRESENT AT NEEDHAM HEALTHCARE CONFERENCE
April 08, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., April 08, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of...